Protagonist Therapeutics Inc (PTGX) Stock AnalysisPTGXStock AnalysisProtagonist Therapeutics Inc

Protagonist Therapeutics, Inc. is a biopharmaceutical company with a technology platform that enables de novo discovery of peptide therapeutics. The Company's programs fall into three therapeutic areas: inflammation and immunology (I&I), hematology, and metabolic diseases. Its clinical and pre-clinical programs address biologically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, obesity dual agonist peptide PN-458, oral small molecule hepcidin functional mimetic PN-8047, and IL-4 and amylin programs. The ICOTYDE (icotrokinra) is used for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. Rusfertide is an investigational injectable mimetic of the natural hormone hepcidin in development for the treatment of the rare blood disorder polycythemia vera (PV). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Protagonist Therapeutics Inc (PTGX) is a good buy right now due to its recent strong earnings report, which showed a Non-GAAP EPS of $2.29, exceeding expectations by $0.36, and a staggering revenue growth of 3746.5% year-over-year, reaching $213.48 million. However, the stock has a current RSI of 29.935, indicating it is oversold, which presents a buying opportunity. The main risk is the recent insider selling, which has increased by 7175.14% over the last month, suggesting potential concerns among insiders about the stock's future performance.

4 analysts cover PTGX: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 94.54.